Literature DB >> 24389984

The association between BRAF (V600E) mutation and pathological features in PTC.

Xin Liu1, Kangkang Yan, Xuejun Lin, Longyu Zhao, Wenxiu An, Chunpeng Wang, Xiaodong Liu.   

Abstract

The BRAF (V600E) mutation is a common genetic alteration in papillary thyroid carcinoma (PTC) and is associated with some pathological features. The association has been widely reported, but results were inconclusive. In this study a meta-analysis was done to explore the association between BRAF(V600E) mutation and pathological features in papillary thyroid carcinoma. Medline, PubMed and Web of Science were searched. A total of 69 studies that included 14,170 PTC patients were identified. The outcomes were from 2004 to October 2013. STATA12.0 software package was used to analyze the data. The result was assessed based on pooled odds ratios (ORs) with 95 % confidence intervals (CIs). The results showed that the BRAF (V600E) mutation was associated with extra-thyroidal extension (OR = 2.09, 95 % CI = 1.69-2.58), advanced TNM stage (OR = 1.90, 95 % CI = 1.62-2.22), lymph node metastasis (OR = 1.68, 95 % CI = 1.41-2.01), multifocality (OR = 1.22, 95 % CI = 1.06-1.40), and recurrence (OR = 2.50, 95 % CI = 1.73-3.59). The meta-analysis suggested the potential roles of BRAF (V600E) mutation in pathological features. BRAF (V600E) might provide prognostic and diagnostic information for papillary thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24389984     DOI: 10.1007/s00405-013-2872-7

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  77 in total

1.  The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors:  Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

2.  Cytopathological review of patients that underwent thyroidectomies based on the diagnosis of papillary thyroid carcinoma by fine needle aspiration cytology but were later found to have benign tumors by histopathology.

Authors:  Mutsukazu Kitano; Iwao Sugitani; Kazuhisa Toda; Motoko Ikenaga; Noriko Motoi; Noriko Yamamoto; Muneki Hotomi; Yoshihide Fujimoto; Kazuyoshi Kawabata
Journal:  Surg Today       Date:  2012-10-18       Impact factor: 2.549

3.  Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.

Authors:  David A Kleiman; Daniel Buitrago; Michael J Crowley; Toni Beninato; Alexander J Veach; Pat B Zanzonico; Moonsoo Jin; Thomas J Fahey; Rasa Zarnegar
Journal:  J Surg Res       Date:  2012-09-08       Impact factor: 2.192

4.  Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct.

Authors:  Alexander Finkelstein; Gillian H Levy; Pei Hui; Avinash Prasad; Renu Virk; David C Chhieng; Tobias Carling; Sanziana A Roman; Julie A Sosa; Robert Udelsman; Constantine G Theoharis; Manju L Prasad
Journal:  Histopathology       Date:  2012-02-15       Impact factor: 5.087

5.  BRAF mutations in an Italian cohort of thyroid cancers.

Authors:  Laura Fugazzola; Deborah Mannavola; Valentina Cirello; Guia Vannucchi; Marina Muzza; Leonardo Vicentini; Paolo Beck-Peccoz
Journal:  Clin Endocrinol (Oxf)       Date:  2004-08       Impact factor: 3.478

6.  BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Authors:  Angela M Costa; Agustín Herrero; Manuel F Fresno; Jonas Heymann; José Antonio Alvarez; Jose Cameselle-Teijeiro; Ginesa García-Rostán
Journal:  Clin Endocrinol (Oxf)       Date:  2007-12-05       Impact factor: 3.478

7.  Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.

Authors:  Haixia Guan; Meiju Ji; Peng Hou; Zhi Liu; Cuifang Wang; Zhongyan Shan; Weiping Teng; Mingzhao Xing
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

8.  Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.

Authors:  Hirotaka Nakayama; Akira Yoshida; Yoshiyasu Nakamura; Hiroyuki Hayashi; Youhei Miyagi; Nobuyuki Wada; Yasushi Rino; Munetaka Masuda; Toshio Imada
Journal:  Anticancer Res       Date:  2007 Sep-Oct       Impact factor: 2.480

9.  Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma.

Authors:  Jonathan Zagzag; Aron Pollack; Linda Dultz; Shumon Dhar; Jennifer B Ogilvie; Keith S Heller; Fang-Ming Deng; Kepal N Patel
Journal:  Surgery       Date:  2013-08-06       Impact factor: 3.982

10.  High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.

Authors:  Gisele Oler; Janete M Cerutti
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

View more
  17 in total

1.  Comparison of the clinicopathological behavior of the follicular variant of papillary thyroid carcinoma and classical papillary thyroid carcinoma: A systematic review and meta-analysis.

Authors:  Jing Yang; Yanping Gong; Shuping Yan; Qingquan Shi; Jingqiang Zhu; Zhihui Li; Qiang Chen; Rixiang Gong
Journal:  Mol Clin Oncol       Date:  2015-04-06

2.  The Role of BRAF V600E in Reducing AUS/FLUS Diagnosis in Thyroid Fine Needle Aspiration.

Authors:  Lei Yin; Yi Tang; Shanshan Yu; Chenglong Wang; Ming Xiao; Yalan Wang; Shu Jun Liu; Lu Gao; Keli Huang; Ling Jin
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

3.  Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma.

Authors:  Woo-Young Sun; Woo-Hee Jung; Ja Seung Koo
Journal:  Tumour Biol       Date:  2015-12-30

4.  Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.

Authors:  Jiao Li; Jun Liang; Teng Zhao; Yansong Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-16       Impact factor: 9.236

5.  Comparison of the clinicopathological features and oncologic outcomes of the classic papillary thyroid carcinoma with tall cell features and tall cell variant.

Authors:  Kwangsoon Kim; Chan Kwon Jung; Dong-Jun Lim; Ja Seong Bae; Jeong Soo Kim
Journal:  Gland Surg       Date:  2022-01

6.  Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.

Authors:  Jian Sun; Jing Zhang; Junliang Lu; Jie Gao; Tao Lu; Xinyu Ren; Huanli Duan; Zhiyong Liang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

7.  The features of contrast enhanced ultrasound and BRAF V600E in papillary thyroid carcinoma.

Authors:  Zi-Mei Lin; Cao-Xin Yan; Yue Song; Yu-Rong Hong; Qing Wen; Yong-Yuan Xu; Min-Qiang Pan; Qin Ye; Pin-Tong Huang
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

8.  Expression of serine/glycine metabolism-related proteins is different according to the thyroid cancer subtype.

Authors:  Woo Young Sun; Hye Min Kim; Woo-Hee Jung; Ja Seung Koo
Journal:  J Transl Med       Date:  2016-06-08       Impact factor: 5.531

9.  Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis.

Authors:  Woon Won Kim; Tae Kwun Ha; Sung Kwon Bae
Journal:  J Otolaryngol Head Neck Surg       Date:  2018-01-09

10.  Expression of glutamine metabolism-related proteins in thyroid cancer.

Authors:  Hye Min Kim; Yu Kyung Lee; Ja Seung Koo
Journal:  Oncotarget       Date:  2016-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.